Skip to main content
. 2019 May 23;14(3):335–342. doi: 10.1007/s11523-019-00644-6

Fig. 2.

Fig. 2

Overall survival in patients with or without chemotherapy after progression on osimertinib (a) and in patients who continued or discontinued osimertinib after progression (b), and post-progression overall survival in patients with or without chemotherapy after progression on osimertinib (c) and in patients who continued or discontinued osimertinib after progression (d). Tick marks indicate censored events. CI confidence interval, OS overall survival, pOS post-progression overall survival